Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 clinical trials
Also written INCA33890.
Its developmentBy Incyte, step by step3 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- INCA33890
- 4
Studies by the year they started
3 studies that test it; most in 2026 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Incyte Corporation (3) · Groupe Oncologie Radiotherapie Tete et Cou (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and ChemotherapyRecruitingPhase 2Incyte CorporationNCT07823322Written as INCA33890How we know
- A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerRecruitingPhase 3Incyte CorporationNCT07284849Written as INCA33890How we know
- A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.Not yet recruitingPhase 2Groupe Oncologie Radiotherapie Tete et CouNCT07876414Written as INCA33890How we know
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsRecruitingPhase 1Incyte CorporationNCT05836324Written as INCA33890How we know
Given beside what is tested · 1 — Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 21, 2026.